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Introduction to Epithelial-Mesenchymal Transition
Epithelial-mesenchymal transition (EMT) is a morphogenic cel-
lular program, whereby stationary epithelial cells convert to a 
motile mesenchymal morphology. The initiation and subsequent 
completion of EMT occurs through the precise coordination 
of numerous molecular events, including activation of EMT-
inducing transcription factors, altered expression of cell-surface 
proteins, reorganization of the actin cytoskeleton and enhanced 
invasive properties.1 Epithelial cells exhibit an organized 
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epithelial-mesenchymal transition (eMT) is an essential 
developmental program that becomes reactivated in adult 
tissues to promote the progression of cancer. eMT has been 
largely studied by examining the beginning epithelial state 
or the ending mesenchymal state without studying the 
intermediate stages. recent studies using trophoblast stem 
(TS) cells paused in eMT have defined the molecular and 
epigenetic mechanisms responsible for modulating the 
intermediate “metastable” stages of eMT. Targeted inactivation 
of MAP3K4, knockdown of CBP or overexpression of SNAi1 
in TS cells induced similar metastable phenotypes. These TS 
cells exhibited epigenetic changes in the histone acetylation 
landscape that cause loss of epithelial maintenance while 
preserving self-renewal and multipotency. A similar phenotype 
was found in claudin-low breast cancer cells with properties 
of eMT and stemness. This intersection between eMT and 
stemness in TS cells and claudin-low metastatic breast cancer 
demonstrates the usefulness of developmental eMT systems 
to understand eMT in cancer.
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apical-basal polarity maintained by the precise arrangement of 
actin filaments and adhesive structures such as tight junctions, 
adherens junctions and desmosomes. Specialized adhesive mol-
ecules, such as cadherins, integrins and other cell-surface pro-
teins, are essential for maintenance of the epithelial phenotype 
by stabilizing cell-cell contacts.2 Conversely, mesenchymal cells 
are characterized by a unique spindle morphology defined by 
a front-back-end polarity and enhanced invasive potential.3,4 
In addition to promoting cellular migration and invasion, the 
transient phenotypic changes associated with formation of the 
mesenchymal state during EMT have been associated with the 
acquisition of stem-like properties.5 This intermediate stage of 
EMT, coined the metastable phenotype, describes the simultane-
ous existence of both epithelial and mesenchymal characteristics 
and is of great importance for understanding the cellular changes 
associated with progression of the EMT program.6 Due to the 
tremendous difficulty in capturing cells in the intermediate states 
of EMT, most studies have focused on the initiation or comple-
tion of EMT. Our recent study describes the development of new 
models using trophoblast stem (TS) cells to examine the interme-
diate stages of EMT.7 One of these TS cell models was isolated 
from conceptuses with a point mutation in MAP3K4, a kinase 
regulating JNK and p38 MAPK pathways, rendering the kinase 
inactive (TSKI4 cells) and resulting in cells in a metastable state 
with properties of both stemness and EMT.8 Studies of TSKI4 cells 
allowed the discovery of epigenetic mechanisms regulating EMT 
in trophoblasts and highlighted an EMT signature overlapping 
with the control of EMT in metastatic breast cancer.7
Classifications of EMT
EMT is essential for the proper formation of the body plan and dif-
ferentiation of many tissues and organs during embryonic devel-
opment. During organ development, epithelia convert between 
epithelia and mesenchyme through multiple rounds of EMT and 
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activation of EMT resulting in organ fibrosis. The third EMT 
subtype occurs during cancer progression, whereby EMT in 
epithelial cancer cells produces cells with increased invasive and 
metastatic capacity. Although the three subtypes of EMT have 
seemingly diverse outcomes, a common set of molecular features 
underlies each EMT event. Critical developmental signaling 
pathways (i.e., Wnt, Notch, Hedgehog and TGFβ) with demon-
strated importance in promoting developmental EMT are reacti-
vated in the generation of EMT-associated pathologies, including 
organ fibrosis and the metastatic spread of cancer (Fig. 1).2,11-15 
Using trophoblast stem (TS) cells as a model system, we will dis-
cuss the molecular and epigenetic mechanisms responsible for the 
the reversible process mesenchymal-epithelial transition (MET).9 
In adult tissue, the EMT program is reactivated during wound 
healing, organ fibrosis and tumor progression. EMTs are classified 
into three main categories based upon involvement in different 
biological processes (Fig. 1).4,10 Developmental EMTs constitute 
the first EMT subtype and include implantation, gastrulation 
and neural crest formation. Developmental EMT events occur 
in a temporally controlled setting and contribute to embryonic 
morphogenesis and tissue remodeling during development. The 
second EMT subtype is associated with wound healing and tis-
sue regeneration in adult tissue and occurs in response to inflam-
mation. Persistent inflammatory signals produce continuous 
Figure 1. Comparison of eMT subtypes in development and cancer metastasis. The first developmental eMT that occurs during implantation of the 
blastocyst into the uterine epithelium (left part) and eMT associated with the metastatic progression of cancer (right part) are shown. MeT indicates 
mesenchymal-epithelial transition.
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maintained in vitro culture conditions by FGF4.28,29 E-cadherin 
and cortical actin are localized around the periphery of TS cell 
epithelial colonies and maintain the integrity of the epithelial col-
onies. Removal of FGF4 induces TS cell differentiation into dif-
ferent trophoblast lineages. Differentiating trophoblasts undergo 
an EMT involving downregulation of E-cadherin expression, 
loss of cortical actin with concomitant gain of filamentous actin, 
and the acquisition of invasiveness. After four days of TS cell 
differentiation following FGF4 withdrawal, the trophoblast 
invasive capacity peaks, as demonstrated by Matrigel invasion 
assays.7,8,30-32 Since TS cell differentiation pathways are essential 
to EMT processes of implantation and placentation, the in vitro 
TS cell differentiation model induced by removal of FGF4 is 
highly useful for interrogating the connections between EMT 
and TS cell differentiation.
The genetically engineered mouse model with targeted inacti-
vation of MAP3K4 (KI4) exhibits defective decidualization, fetal 
growth restriction and implantation defects attributable to tro-
phoblast hyperinvasion and dysregulated EMT.33 When cultured 
in non-differentiating conditions in the presence of FGF4, TSKI4 
cells demonstrate a 20-fold increase in invasion compared with 
wild-type trophoblast stem cells (TSWT cells). In addition, TSKI4 
cells cultured in the presence of FGF4 exhibit a more robust inva-
sive capacity than wild-type trophoblasts differentiated for four 
days (TINV cells) by removal of FGF4. Furthermore, the acqui-
sition of the mesenchymal phenotype in TSKI4 cells is demon-
strated by several phenotypic and molecular changes, including 
loss of epithelial apical-basal polarity and a gain of mesenchymal 
front-back polarity, reduced levels of peripheral E-cadherin and 
cortical actin, and acquired expression of mesenchymal mark-
ers such as N-cadherin and vimentin. Importantly, TSKI4 cells 
maintain self-renewal properties as demonstrated by expression 
of the stem cell markers CDX2 and ESRRβ at levels similar to 
TSWT cells.7,8,34,35 Maintenance of multipotency is also exhibited 
by the ability of TSKI4 cells to differentiate into each of the tro-
phoblast lineages. These findings in TSKI4 cells directly contrast 
with that of terminally differentiated TINV cells that completely 
lack stemness markers CDX2 and ESRRB and no longer divide. 
Stemness properties of TSKI4 cells were definitively demonstrated 
by blastocyst chimera experiments, whereby TSKI4 cells injected 
into donor blastocysts reconstituted the extraembryonic stem cell 
compartment and differentiated in vivo into giant cells and cells 
of the ectoplacental cone.7,8 The simultaneous existence of stem-
ness and EMT properties indicates that TSKI4 cells represent a 
metastable EMT state (Fig. 2). Metastable EMT is defined as 
an intermediate stage in the progression of the EMT program, 
whereby cells express attributes of both epithelial and mesenchy-
mal phenotypes while simultaneously expressing stem cell mark-
ers. Due to the transient nature of the metastable phenotype, it 
is difficult to observe this intermediate stage in the progression 
of EMT.4,6 From studies with TSKI4 cells, we have shown that 
the simultaneous maintenance of stemness and the acquisition 
of EMT properties promote an unrestricted trophoblast invasive 
potential. During both development and cancer progression, 
hyperinvasion resulting from uncontrolled EMT signaling events 
can be detrimental to survival. TSKI4 cells in metastable EMT 
first developmental EMT event, implantation and the initiation 
of placenta formation. Furthermore, we will examine the connec-
tions between EMT and stemness and discuss the considerable 
overlap between signaling pathways that regulate developmental 
EMT and EMT-associated pathologies.
The First Developmental EMT Event
Implantation is the first developmental EMT event and is essen-
tial for proper placental development necessary to support a 
developing fetus. Failure of implantation prevents all succes-
sive EMT processes, such as gastrulation and neural crest for-
mation.16 During implantation, the epithelial trophoectoderm 
of the blastocyst undergoes EMT with changes in cell polarity, 
motility and adhesiveness (Fig. 1). These changes in cell polar-
ity are accompanied by extension of protrusive structures and 
loss of expression of the master-regulator of the epithelial pheno-
type E-cadherin, which are necessary for trophoblast invasion of 
the uterine epithelium. After implantation, the epithelial polar 
trophoectoderm overlying the inner cell mass of the blastocyst 
differentiates into specialized trophoblast lineages to form a 
functional placenta. Invading trophoblasts generated through 
differentiation penetrate and remodel the maternal blood vessels, 
forming the chorionic villi. Considered the functional unit of the 
placenta, the chorionic villi provide a large surface area for nutri-
ent exchange between mother and developing fetus. Formation 
of the chorionic villi, requiring extensive blood vessel remod-
eling, constitutes the second developmental EMT event.17-20 
Precise regulation of trophoblast EMT is essential for success-
ful implantation and placentation. Under normal conditions, 
the trophoblast invasive potential is restricted both temporally 
and spatially according to trophoblast differentiation signals. 
Several disease states are resultant from dysregulated trophoblast 
EMT. Two notable pathologies, preeclampsia and accreta, mani-
fest as clinical outcomes directly linked to aberrant trophoblast 
invasion.21 Preeclampsia is the result of decreased or absent tro-
phoblast invasion and remodeling of the maternal arteries.22,23 
Conversely, placenta accreta is defined as abnormal adherence 
of the placenta to the uterine epithelium resulting from exces-
sive invasion of hyperinvasive trophoblasts into the uterine wall. 
Trophoblasts at the maternal-placental interface have dem-
onstrated increased invasive capacity. Rather than being more 
differentiated and syncytiotrophoblastic in nature, these tro-
phoblasts resemble self-renewing and highly proliferative cyto-
trophoblasts (i.e., trophoblast stem cells) in the early stages of 
implantation and placenta development.24,25 Due to the similar-
ity between invasive trophoblasts and malignant cancer cells, it 
is likely that similar regulatory paradigms persist between these 
EMT subtypes.26
Molecular Mechanisms of Trophoblast EMT
Trophoblast stem (TS) cells can be isolated from the tropho-
ectoderm of the developing blastocyst and the extraembryonic 
ectoderm of the E6.5 conceptus.16,27 Self-renewal in TS cells, 
defined as cell division with the maintenance of multipotency, is 
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via direct repression of E-cadherin in 
several epithelial cell models, includ-
ing human mammary epithelial 
cells.5,41,42 As TS cells are differentiated 
in vitro, via the withdrawal of FGF4, 
SNAI1 expression gradually increases 
starting at 4 d of differentiation. The 
gradual increase in SNAI1 expression 
coincides with the peak of trophoblast 
invasion, thereby functionally linking 
the trophoblast invasive potential to 
the levels of SNAI1 expression.7 The 
expression of SNAI1 has also been 
demonstrated in the invading extravil-
lous trophoblasts in human placenta 
development, further signifying the 
importance of SNAI1 to the induction 
of trophoblast EMT.20,25 Concurrent 
with the increases in SNAI1 expression 
upon TS cell differentiation, expres-
sion levels of the TGFβ-responsive 
transcription factor LEF1 exhibit an 
almost identical pattern of induction. 
The SNAI1 promoter contains LEF1 
binding elements, suggesting that 
LEF1 and SNAI1 function coopera-
tively during TGFβ-mediated EMT 
programs.43 TSKI4 cells with properties 
of stemness and EMT express elevated 
levels of the EMT-inducing transcrip-
tion factors SNAI2, TWIST1 and 
LEF1, but not SNAI1. This expression 
pattern contrasts with EMT induced 
by differentiation where SNAI1 and 
LEF1 are induced, but not SNAI2 or 
TWIST1, suggesting that different 
sets of transcription factors may be 
used to induce EMT in the context of 
stemness.
As mentioned above, ectopic 
expression of SNAI1 has been shown 
to induce EMT in several cell types. Similarly, in TS cells, 
expression of SNAI1 (TSSNAI1 cells) robustly induces EMT.5 
Characteristic of EMT, TSSNAI1 cells have a loss of E-cadherin 
expression and exhibit a mesenchymal spindle-like morphology, 
increased expression of mesenchymal markers N-cadherin and 
vimentin, and a functional increase in trophoblast invasiveness. 
Interestingly, TSSNAI1 cells are 66% less invasive than TSKI4 cells. 
In addition, TSSNAI1 cells are less stem-like than TSKI4 cells, show-
ing a 20–50% decrease in the expression of stemness genes and 
a reduced growth rate.7 These findings suggest that maintenance 
of stemness is important for regulating the trophoblast invasive 
potential during the induction of EMT. From a full panel of 
seven well-characterized EMT-regulatory transcription factors 
(Fig. 2), ETS1, LEF1, ZEB1 and FOXC2 were the only EMT-
regulatory transcription factors significantly induced during the 
have proven to be a unique tool to define novel transcriptional 
and epigenetic reprogramming events and signaling pathways 
important for induction of the EMT program.
Transcriptional Regulation of Trophoblast EMT
Expression of the adhesive glycoprotein and master-regulator 
of the epithelial phenotype, E-cadherin, is transcriptionally 
repressed by several transcription factors of the SNAIL and ZEB 
superfamilies. In multiple EMT subtypes, SNAI1, SNAI2, ZEB1 
and ZEB2 are coordinately upregulated during the initiation and 
progression of EMT. SNAI1 and SNAI2 are well-characterized 
transcriptional repressors of E-cadherin and function by bind-
ing a canonical E-box consensus sequence within the E-cadherin 
gene promoter.36-40 Ectopic expression of SNAI1 can induce EMT 
Figure 2. Characteristics of intermediate stages of eMT in trophoblast stem cells. TSwT and TSKi4 cells 
were isolated from wild-type or MAP3K4 kinase-inactive conceptuses, respectively. TSshCBP cells are 
TSwT cells expressing CBP shrNA. TSSNAi1 cells are TSwT cells overexpressing SNAi1. TSwT, TSKi4, TSshCBP and 
TSSNAi1 cells are cultured under non-differentiating conditions in FGF4. TiNv cells are invasive tropho-
blasts cultured for four days under differentiating conditions and isolated from Matrigel-coated tran-
swell invasion chambers. The + symbol indicates presence of the trait; the - symbol indicates absence 
of the trait. The quantity of + symbols indicates the relative degree of presence of the trait.
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that an alternative repressive modification is dominant in TS 
cells and that the repressive H3K27me3 modification becomes 
important only after implantation, likely driving later lineage 
commitment decisions critical to the formation of the placenta. 
This could explain why mutants of Polycomb complex members, 
such as EZH2, SUZ12 and EED, demonstrate defects later dur-
ing development of extraembryonic tissues while not directly 
affecting TS cells.55,56 Specifically, EED mutants exhibit tro-
phoblast differentiation defects demonstrated by failure to pro-
duce secondary invasive trophoblast giant cells, suggesting that 
H3K27me3 modifications might be important during activation 
of a specific transcriptional program.57,60 For example, invading 
trophoblast giant cells play important roles during the EMT 
events of placentation. Furthermore, the activating H3K4me3 
and the repressive H3K9me3 modifications demonstrate impor-
tance in TS cell maintenance, but the biological connections to 
EMT are unclear.47 Further studies with these histone methyla-
tion marks could provide insight into the importance of these 
modifications in specific transcriptional and EMT programs.
Histone acetylation is associated with active gene transcription 
due to its ability to decondense and open chromatin.61,62 Recent 
work from our lab has demonstrated that global loss of histone 
acetylation is a dominant mechanism for the activation of TS cell 
differentiation programs. As TS cells are differentiated by FGF4 
withdrawal, acetylation of all four core histones H2A, H2B, H3 
and H4 is globally reduced over a 5-day time-course of differ-
entiation. Occurring in parallel with trophoblast differentiation 
programs, the induction of trophoblast EMT is also epigeneti-
cally regulated by histone acetylation patterns.7 The discovery 
that trophoblast EMT programs are regulated by epigenetic 
mechanisms of histone acetylation stemmed from the observa-
tion of overlapping phenotypes between KI4 mice and mice defi-
cient for the histone acetyltransferase CBP.33,63,64 KI4 and CBP 
knockout mice both display skeletal, neural tube and craniofacial 
defects combined with growth retardation and embryonic lethal-
ity. Biochemical assays, including kinase and histone acetylation 
assays, demonstrate that regulation of CBP acetyltransferase 
activity is controlled by MAP3K4/JNK-dependent phosphoryla-
tion of CBP. Loss of MAP3K4 activity results in diminished CBP 
histone acetyltransferase activity. Furthermore, loss of CBP activ-
ity through either loss of MAP3K4 activity in TSKI4 cells or by 
shRNA knockdown of CBP in TSshCBP cells results in the selective 
loss of H2A and H2B acetylation and the induction of a mesen-
chymal phenotype. Similar to TSKI4 cells, TSshCBP cells exhibit loss 
of apical-basal polarity and increased expression of mesenchymal 
markers and invasiveness, while maintaining the expression of 
stemness genes (Fig. 2). Examination of self-renewing TSKI4 and 
TSSNAI1 cells with properties of stemness and EMT reveals selec-
tive loss of acetylation from histones H2A and H2B, suggesting 
a specific role for H2A and H2B acetylation in regulation of TS 
cell EMT (Fig. 2). In support of this conclusion, three separate 
models of TS cell EMT (TSKI4, TSSNAI1 and TSshCBP cells) exhibit 
selective inhibition of H2A and H2B acetylation (Fig. 2). For 
TSKI4 cells, this selective loss of H2A and H2B acetylation occurs 
independently of changes in H3K4 and H3K9 histone methyla-
tion patterns, indicating that changes in histone acetylation but 
SNAI1-mediated EMT program in TS cells. Expression levels of 
LEF1 and ZEB1 were induced 50 to 100-fold, indicating that 
these transcription factors function simultaneously with SNAI1 
to execute trophoblast EMT.7 It is possible that members of the 
EMT-regulatory transcription factor repertoire of SNAI1, LEF1, 
ZEB1 and ETS1 have different roles in the initiation vs. execu-
tion of trophoblast EMT.
Epigenetic Regulation of Trophoblast EMT
Recent studies have demonstrated an increasingly significant role 
of epigenetic mechanisms for regulation of critical developmental 
programs important for establishing and maintaining cell lin-
eage fates.7,44,45 The first cell fate decision during development 
generates two primary lineages of the blastocyst, the trophoec-
toderm that differentiates into the trophoblast subtypes of the 
placenta and the inner cell mass that forms the embryo.19,27 The 
main mechanisms of trophoblast epigenetic regulation include 
DNA methylation, histone modifications and X-chromosome 
inactivation.46,47
In contrast to pluripotent embryonic stem cells responsible 
for the formation of the embryo, DNA of the trophoblast epig-
enome is hypomethylated. This hypomethylation is critical for 
implantation and trophoblast differentiation. As trophoblasts 
differentiate into a more invasive subtype, occurring simultane-
ously with the progression of EMT, the trophoblast epigenome 
is continually demethylated. Reduced DNA methylation pro-
motes activation of genetic information critical to trophoblast 
lineage commitment.47-51 Despite global hypomethylation of the 
trophoblast lineage, DNA methylation is indispensable for extra- 
embryonic development. For example, the DNA methyl-
transferase regulatory factor DNMT3L is highly expressed in 
the epithelial trophoectoderm and DNMT3L-deficient mice 
exhibit multiple trophoblast defects, including failure to form 
syncytiotrophoblasts of the placenta.52-54 Furthermore, recent 
genome-wide sequencing studies have demonstrated that DNA 
hypomethylation is located primarily in intergenic regions, which 
raises the question of the importance of DNA methylation for the 
direct control of genetic information.
Histone modifications comprise the second layer of trophoblast 
epigenetic regulation. Gene expression levels are controlled by 
the degree of chromatin compaction, which is mediated by wrap-
ping DNA around an octamer of four core histones H2A, H2B, 
H3 and H4. The charged tails of histones are often modified by 
acetylation and methylation marks, which generally contribute 
to the respective activation or repression of genetic information. 
The repressive histone modification H3K27me3 conferred by the 
multi-subunit Polycomb complex has been extensively studied 
for control of gene expression during differentiation of embry-
onic lineages. Immunohistochemistry of the mouse blastocyst 
reveals reduced levels of H3K27me3 in the trophectoderm com-
pared with the inner cell mass.47,55-58 Furthermore, genome-wide 
sequencing studies demonstrate that few promoters in TS cells 
are marked by this modification.59 These findings contrast with 
post-implantation stage extraembryonic tissues, where high gene-
specific levels of H3K27me3 are detected. These results suggest 
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Furthermore, the claudin-low subtype of breast cancer, which is 
characterized by its EMT features, also exhibits stem-like prop-
erties, as demonstrated by overlapping gene expression profiles 
with breast cancer stem cells identified by the CD44+/CD24-/low 
antigenic phenotype. Collectively, these studies reveal a connec-
tion between the cellular plasticity associated with the induction 
of EMT and the maintenance of stem-like characteristics.73-78 In 
the context of EMT and stemness, the importance of identifying 
TSKI4 cells is that they were the first example of a point mutation 
targeting the activity of a kinase (MAP3K4) that causes loss of 
epithelial cell maintenance, while allowing a self-renewing, mul-
tipotent stem cell to be in a permanent metastable EMT. The 
TSKI4 cell phenotype clearly shows that dysregulation of kinase 
signaling networks can induce a metastable EMT with properties 
arguably similar to those proposed for the controversial tumor ini-
tiating or cancer stem cell.79 These results suggest that character-
ization of these signaling networks might provide new therapeutic 
strategies to reverse these EMT-associated pathologies.
Connections between Trophoblast EMT  
and Tumor Progression
Cancer metastasis is responsible for the majority of cancer related 
deaths, and EMT is believed to induce the cellular traits associ-
ated with the metastatic progression of cancer. In recent years, evi-
dence for the role of EMT in the metastatic progression of cancer 
has continued to build.80,81 Multiple reports demonstrate that the 
very same transcription factors (i.e., SNAI1, SNAI2, TWIST1), 
adhesive structures (i.e., aν-β-integrin family) and signaling 
pathways (i.e., Tgfβ, Notch, Hedgehog) controlling defined 
EMT programs are also responsible for regulating tumor progres-
sion.15,82 For instance, loss of E-cadherin expression is a hallmark 
of metastatic carcinoma and expression of the transcriptional 
repressor of E-cadherin SNAI1 correlates with poor survival rates. 
Additionally, SNAI1 expression levels are elevated at the invading 
front of colorectal tumors.36,38,40,83-92 The controversy surrounding 
the role of EMT in cancer metastasis stems from the difficulty 
of directly following the progression of EMT during tumor for-
mation. In support of the connection between EMT and cancer 
metastasis, both proteomic and multiphoton microscopy analysis 
demonstrate the conversion of circulating mammary tumor cells 
to the mesenchymal phenotype.93-95 Furthermore, the phenotypic 
similarity between the primary mammary tumor and the second-
ary tumor metastasis suggests a role for both EMT and MET in 
the metastatic progression of cancer.
In 1902 John Beard proposed that many cancers are tropho-
blastic-like, in part, because their tissue invasive nature is similar to 
the invasiveness of the trophoblast during placentation.26,96 Today, 
the origin of cancer stem cells is controversial. It remains unclear 
if different cancer stem cells arise from multipotent tissue stem 
cells (similar to TSKI4 or TSSNAI1 cells) or from reprogramming of 
differentiated cells that revert to a stem cell-like phenotype (simi-
lar to primary mammary epithelial cells expressing SNAI1).97-100 
To begin addressing this question, we identified an intersecting 
EMT gene signature from analysis of microarray gene expression 
data shared by TSKI4 cells developmentally entering EMT and 
not methylation are responsible for the induction of EMT in TS 
cells. In addition to the examination of histone acetylation pat-
terns, genome-wide H2BK5Ac ChIP-seq studies coupled with 
gene expression analysis revealed that genes both significantly 
downregulated and hypoacetylated in TSKI4 cells clustered into 
pathways critical for maintenance of the actin cytoskeleton, focal 
adhesions and the extracellular matrix.7 These results highlight 
the importance of H2B acetylation for maintenance of the tro-
phoblast epithelial phenotype. To our knowledge, this is the first 
analysis directly connecting selective histone acetylation marks to 
the transcriptional activation of the trophoblast EMT program. 
We hypothesize that loss of H2A and H2B acetylation is an epi-
genetic signature critical to the induction of EMT metastability. 
Although this intermediate EMT phenotype is usually transient 
in nature, TSKI4 and TSshCBP cells are uniquely paused in the meta-
stable EMT state due to perturbation of the upstream modifier 
CBP and subsequent incomplete modulation of the epigenetic 
landscape.
Trophoblast EMT and Stemness
Several studies have reported the interrelationship between EMT 
and stemness. The transcription factor SNAI1 is well character-
ized for its ability to induce EMT in multiple cell-based systems. 
Interestingly in mammary epithelial cells, overexpression of 
SNAI1 or TWIST1 not only induces EMT, but also results in 
the acquisition of stem cell properties.5,41 Furthermore, TWIST1 
promotes EMT while bypassing cellular senescence, connecting 
EMT to an unrestricted proliferative capacity.65-67 More recently, 
mesenchymal-epithelial transition (MET), the reverse process of 
EMT, was shown to occur in parallel with the reprogramming of 
fibroblasts to induced pluripotent stem cells (iPS).68,69 Similarly in 
TS cells, the coexistence of EMT and stemness was demonstrated 
by the comparison of properties between TSKI4 and TSSNAI1 cells. 
For example, TSKI4 cells are more invasive than TSSNAI1 cells even 
though TSSNAI1 cells exhibit more profound mesenchymal proper-
ties (Fig. 2). TSKI4 cells also have more robust stem cell features, 
including greater expression of the trophoblast stem cell marker 
CDX2.7,70 Thus, TSKI4 cells, characterized as self-renewing, mul-
tipotent stem cells in a highly invasive intermediate EMT state, 
highlight the association between stemness properties and meta-
stable EMT. Obviously, such a phenotype has the potential to 
cause severe disease pathologies. During the pathophysiological 
progression of placenta accreta, trophoblasts at the maternal-pla-
cental interface with increased invasive capacity resemble self-
renewing and highly proliferative TS cells in the early stages of 
implantation and placenta development. Although the genetic 
basis for accreta is unknown, the phenotype highlights the ability 
of stem cells to display EMT properties.25 In addition to TSKI4 
cells, EMT metastability has been reported in colorectal cancer 
cells and progenitor cells of various organs undergoing EMT. 
During colorectal tumor remodeling and metastasis, immunohis-
tochemistry of colon adenocarcinomas demonstrated the simul-
taneous retention of branched epithelial structures stabilized by 
E-cadherin and invading mesenchymal protrusions marked by 
high levels of β-catenin, SNAI1 and fibronectin expression.71,72 
www.landesbioscience.com Cell Cycle 2871
We propose that studies aimed at understanding the regulatory 
mechanisms restricting EMT and invasiveness of primary epi-
thelial stem cells can provide insight into signaling networks 
responsible for management of metastatic cancer. Due to the 
intersecting features of EMT subtypes, a complete picture of this 
complex cellular program, which is fundamental to development 
and reactivated in adult tissues during disease progression, can 
now be studied from multiple biological perspectives. The change 
in histone acetylation observed with TSKI4, TSshCBP, TSSNAI1 and a 
subset of intersecting EMT signature genes in claudin-low breast 
cancer suggests that an “EMT acetylome” may control signaling 
networks regulating properties of epithelial maintenance and 
EMT. Defining the acetylome network could potentially reveal a 
strategy to reverse metastable EMT by stabilizing the non-inva-
sive epithelial phenotype. Significant therapeutic interest in the 
reversal of EMT is highlighted by the exploration of synthetic 
molecular compounds to restore E-cadherin expression.101-103 The 
controlled induction of MET could have benefit for the reversal 
of several pathophysiological states where there is a dysregulated 
EMT.
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claudin-low breast cancer. Similar to human claudin-low breast 
cancer cell lines and tumors, TSKI4 cells exhibit an increase in the 
mesenchymal markers VIM, CDH2, SNAI2 and TWIST1 with 
loss of the epithelial differentiation and cell adhesion markers 
CD24, KRT7/8/19 and CLDN4.7 In concordance with the stem 
cell-like CD44+/CD24-/low and EpCAM-/CD49f+ antigenic phe-
notypes of breast tumor initiating cells and mammary stem cells, 
gene expression profiling demonstrated that claudin-low tumors 
have the lowest expression of epithelial differentiation markers, 
while exhibiting the highest expression of mesenchymal mark-
ers.76 With a few notable exceptions such as SNAI2, TWIST1, 
VIM and CDH2 (N-cadherin), many of the genes in this EMT 
signature are uncharacterized with respect to EMT. It is hypoth-
esized that this gene signature defines a novel set of genes with 
importance in EMT and potentially cancer metastasis. Many of 
the intersecting genes have a correlative loss of expression and loss 
of H2BK5Ac in both TSKI4 and claudin-low breast cancer cells.7 
Thus, even though claudin-low breast cancer cells do not have the 
selective loss of histone H2A and H2B acetylation seen in TSKI4 
cells, specific genes within this intersecting EMT signature have 
loss of H2BK5 acetylation. These findings suggest that epigenetic 
changes in the acetylation landscape of tumor cells in EMT may 
be important for regulating the metastatic progression of cancer.
Conclusions and Outlook
Unlike cancer metastasis, trophoblast invasive potential is tem-
porally and spatially restricted during normal development. 
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